Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Trump Signs FTC Law That Allows for Biosimilar Scrutiny

President Donald Trump signed a bill into law that requires pharmaceutical companies to provide details of biosimilar deals to the Federal Trade Commission for antitrust scrutiny.

Read More »

Study Shows Drugs on FDA Shortage List Are Likely to See Price Hikes

According to a drug shortage list provided by the U.S. Food and Drug Administration, there have been more than 100 drugs that have faced shortages during 2018.

Read More »

Why Does Immunotherapy Cost So Much?

Immunotherapy – reprogramming the immune system to attack cancer cells – is a rapidly growing and promising field in cancer research and treatment.

Read More »

PTC’s SMA drug shows promise in two studies

PTC Therapeutics announced interim data from part 1 of the company’s open-label clinical trials of risdiplam (RG7916) for Type 1, 2 and 3 spinal muscular atrophy (SMA).

Read More »

Sanofi, Regeneron skin cancer drug gets FDA nod

Sanofi SA’s skin cancer drug Libtayo, made in partnership with Regeneron Pharmaceuticals Inc., was approved by the U.S. Food and Drug Administration.

Read More »

Novo Nordisk to cut 250 jobs in the United States

Denmark’s Novo Nordisk will cut around 250 jobs in the United States, but the drugmaker will also hire an as-yet undetermined number of staff to new positions.

Read More »

U.S. FDA approves Lilly migraine drug; price same as rivals

The U.S. Food and Drug Administration approved Eli Lilly and Co.’s migraine drug Emgality, marking the third approval from a promising new class of treatments for the often debilitating headaches.

Read More »

Merck’s Frazier to remain CEO of the U.S. drugmaker beyond 2019

Merck & Co. Inc. Chief Executive Officer Kenneth Frazier will remain in the role beyond 2019 after scrapping a policy requiring the drugmaker’s CEOs to retire at the age of 65.

Read More »

Gilead to launch generic hepatitis drugs

Gilead Sciences Inc. plans to launch generic versions of the company’s hepatitis C drugs in the United States, at a time when regulators are looking to lower healthcare costs.

Read More »

Drug shortages may add $230 million to annual U.S. drug costs

Prescription drug shortages may drive up prices twice as much as they would rise with medicines in abundant supply, adding $230 million a year to U.S. drug costs, a new study estimates.

Read More »

UK rejects adult Novartis CAR-T therapy

Health authorities in England rejected a pricey CAR-T cell therapy from Novartis for adults with blood cancer, two weeks after endorsing Kymriah’s use in children and young people.

Read More »

AstraZeneca plots China robot offensive to counter price cuts

With smart cancer diagnostics, one-stop-shop diabetes kits and AI systems to improve ambulance pick-ups for patients with chest pain, AstraZeneca aims to move from simply supplying drugs to become a broad healthcare provider in China.

Read More »

Novo Nordisk lays off 400 staff in R&D unit

Novo Nordisk said the world’s top maker of diabetes drugs will lay off 400 staff in Denmark and China as part of a broader restructuring of the company’s research and development organization.

Read More »

U.S. regulator approves Teva migraine drug, shares rise

Shares of Israeli drugmaker Teva Pharmaceutical Industries rose more than 5 percent after the U.S. Food and Drug Administration approved the company’s new migraine treatment.

Read More »

Amgen’s Aimovig Starts Strong, Multiple Myeloma Drug Wows at Conference

Amgen unveiled data at a multiple myeloma conference for AMG-420, which targets B-cell maturation antigen (BCMA).

Read More »

Roche faces UK pricing row over multiple sclerosis drug Ocrevus

Roche faces a fresh row over drug pricing in Britain, following a decision by the body responsible for medicine use within the state health service not to approve the company’s drug Ocrevus for treating a highly disabling form of multiple sclerosis (MS).

Read More »

FDA approves Tetraphase Pharma’s antibiotic

U.S. health regulators approved Tetraphase Pharmaceuticals Inc.’s drug to treat complicated intra-abdominal infections.

Read More »

Novartis wins EU approval for blood cancer therapy Kymriah

Novartis received European approval for Kymriah, the Swiss drugmaker’s gene-modifying therapy for blood cancer.

Read More »

U.S. health secretary says agency has power to eliminate drug rebates

U.S. Health and Human Services Secretary Alex Azar said it was within his agency’s power to eliminate rebates on prescription drug purchases, a key element of the Trump administration’s plan to lower prescription medicine costs.

Read More »

Express Scripts staking out million dollar gene therapies

Express Scripts Holding Co. built a multi-billion enterprise pressuring drug companies to lower their prices for U.S. patients. Now the pharmacy benefit manager is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!

Subscribe

Ad Right Bottom